Ginkgo Bioworks (DNA) Competitors $7.04 -0.33 (-4.45%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNA vs. ARWR, CNTA, GLPG, IDYA, ARQT, TVTX, APGE, AGIO, HRMY, and EWTXShould you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Arrowhead Pharmaceuticals (ARWR), Centessa Pharmaceuticals (CNTA), Galapagos (GLPG), IDEAYA Biosciences (IDYA), Arcutis Biotherapeutics (ARQT), Travere Therapeutics (TVTX), Apogee Therapeutics (APGE), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Ginkgo Bioworks vs. Arrowhead Pharmaceuticals Centessa Pharmaceuticals Galapagos IDEAYA Biosciences Arcutis Biotherapeutics Travere Therapeutics Apogee Therapeutics Agios Pharmaceuticals Harmony Biosciences Edgewise Therapeutics Ginkgo Bioworks (NYSE:DNA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends. Does the media favor DNA or ARWR? In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 4 mentions for Ginkgo Bioworks. Arrowhead Pharmaceuticals' average media sentiment score of 1.60 beat Ginkgo Bioworks' score of 0.40 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community prefer DNA or ARWR? Arrowhead Pharmaceuticals received 525 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 65.51% of users gave Arrowhead Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformGinkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Arrowhead PharmaceuticalsOutperform Votes54965.51% Underperform Votes28934.49% Is DNA or ARWR more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Ginkgo Bioworks' return on equity of -58.54% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks-298.78% -58.54% -34.24% Arrowhead Pharmaceuticals N/A -236.60%-64.09% Do analysts rate DNA or ARWR? Ginkgo Bioworks presently has a consensus target price of $4.58, suggesting a potential downside of 37.92%. Arrowhead Pharmaceuticals has a consensus target price of $41.44, suggesting a potential upside of 198.38%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders & institutionals have more ownership in DNA or ARWR? 78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, DNA or ARWR? Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGinkgo Bioworks$227.04M1.88-$892.87M-$10.68-0.69Arrowhead Pharmaceuticals$2.50M762.93-$599.49M-$5.17-2.69 Which has more volatility & risk, DNA or ARWR? Ginkgo Bioworks has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. SummaryArrowhead Pharmaceuticals beats Ginkgo Bioworks on 11 of the 18 factors compared between the two stocks. Get Ginkgo Bioworks News Delivered to You Automatically Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNA vs. The Competition Export to ExcelMetricGinkgo BioworksBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$428.29M$3.00B$5.57B$18.96BDividend YieldN/A1.89%5.11%4.03%P/E Ratio-0.5630.4222.4432.71Price / Sales1.88498.92394.0927.84Price / CashN/A168.6838.1817.53Price / Book0.343.206.774.47Net Income-$892.87M-$72.35M$3.22B$1.02B7 Day Performance-6.59%1.46%1.49%0.50%1 Month Performance30.33%8.79%4.00%-2.83%1 Year PerformanceN/A-22.36%16.21%4.36% Ginkgo Bioworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNAGinkgo Bioworks0.596 of 5 stars$7.04-4.5%$4.58-35.0%-79.3%$408.27M$227.04M-0.54640Upcoming EarningsNews CoverageARWRArrowhead Pharmaceuticals3.6149 of 5 stars$13.52+2.0%$41.44+206.5%-38.6%$1.86B$2.50M-2.62400Upcoming EarningsNews CoveragePositive NewsCNTACentessa Pharmaceuticals2.5652 of 5 stars$13.71-0.6%$27.71+102.1%+49.7%$1.83B$6.85M-8.96200News CoveragePositive NewsGLPGGalapagos0.6201 of 5 stars$26.87+0.0%$25.33-5.7%-5.4%$1.77B$288.19M0.001,310Options VolumeHigh Trading VolumeIDYAIDEAYA Biosciences3.7119 of 5 stars$19.75+3.9%$53.58+171.3%-50.5%$1.73B$7M-5.9880Upcoming EarningsPositive NewsARQTArcutis Biotherapeutics2.7566 of 5 stars$14.53-0.5%$18.80+29.4%+79.2%$1.72B$196.54M-8.12150Upcoming EarningsPositive NewsTVTXTravere Therapeutics2.934 of 5 stars$19.34+5.5%$32.08+65.9%+276.3%$1.72B$233.18M-4.72460News CoveragePositive NewsAPGEApogee Therapeutics2.222 of 5 stars$37.86+2.7%$92.17+143.4%-22.0%$1.70BN/A-15.6591News CoveragePositive NewsAGIOAgios Pharmaceuticals4.2368 of 5 stars$29.62+0.6%$56.57+91.0%-8.6%$1.70B$36.50M2.61390Earnings ReportAnalyst RevisionNews CoverageHRMYHarmony Biosciences4.8285 of 5 stars$29.36-0.8%$53.33+81.7%-4.7%$1.68B$714.73M13.91200Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsEWTXEdgewise Therapeutics3.2197 of 5 stars$15.68+5.7%$40.13+155.9%-8.6%$1.64BN/A-10.4560Upcoming EarningsAnalyst ForecastShort Interest ↑News CoveragePositive News Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Galapagos Competitors IDEAYA Biosciences Competitors Arcutis Biotherapeutics Competitors Travere Therapeutics Competitors Apogee Therapeutics Competitors Agios Pharmaceuticals Competitors Harmony Biosciences Competitors Edgewise Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DNA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DNA Stock Free DNA Stock Alerts